{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:54:39Z","timestamp":1780379679471,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T00:00:00Z","timestamp":1405555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jdiacomp.2014.07.007","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T13:30:43Z","timestamp":1405690243000},"page":"880-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"Bernard","family":"Charbonnel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Tinahones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Puig","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0055","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)","volume":"36","author":"Ahr\u00e9n","year":"2013","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2014.07.007_bb0015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20132013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0160","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0120","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.2337\/diacare.20.12.1822","article-title":"Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes","volume":"20","author":"Avignon","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0110","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6823-11-3","article-title":"Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: A retrospective database analysis","volume":"11","author":"Bonafede","year":"2011","journal-title":"BMC Endocrine Disorders"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0125","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2337\/diacare.22.6.904","article-title":"How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes?","volume":"22","author":"Bouma","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0095","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1575-0922(09)71946-1","article-title":"Gastrointestinal hormones in food intake control [Article in Spanish]","volume":"56","author":"Crespo","year":"2009","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0030","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","article-title":"Hypoglycemia in diabetes","volume":"26","author":"Cryer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0205","unstructured":"Diamant M, Nauck M, Shaginian R, Malone, J., Cleall, S., de Vries, D., et al. Exenatide BID vs insulin lispro TIDM added to titrated insulin glargine QD in metformin-treated T2DM patient resulted in similar glycemic control but weight loss and less hypoglycemia: The 4B study. Abstract presented at the 73rd Scientific Sessions of the American Diabetes Association, June 21\u201325, 2013; Chicago, IL; http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=795037e5-ca6e-44a8-8b54-cfb1400cd733&cKey=f35d109e-da62-4d3c-a9a1-a9dd25395a9f&mKey=%7b89918D6D-3018-4EA9-9D4F-711F98A7AE5D%7d. Last accessed May 27 2014."},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0115","author":"European Medicines Agency"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0195","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/193229681200600505","article-title":"Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes","volume":"6","author":"Farrokhi","year":"2012","journal-title":"Journal of Diabetes Science and Technology"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0060","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diabres.2008.09.037","article-title":"Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea","volume":"83","author":"Gao","year":"2009","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0005","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4158\/EP13176.CS","article-title":"American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary","volume":"19","author":"Garber","year":"2013","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0025","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0040","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0150","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.12076","article-title":"Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin","volume":"15","author":"Kapitza","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ecl.2012.03.004","article-title":"Insulin therapy in type 2 diabetes mellitus","volume":"41","author":"Leahy","year":"2012","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0140","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0155","unstructured":"Meier, J.J., Rosenstock J., Hincelin-M\u00e9ry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., et al (2014). Effect of lixisenatide vs. liraglutide on glycemic control, gastric emptying, and safety parameters in optimized insulin glargine T2DM\u00b1metformin. Diabetes, 63 (Suppl. 1):A262 (Abstract 1017-P)."},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/qjmed\/hcq112","article-title":"Exenatide therapy in insulin-treated type 2 diabetes and obesity","volume":"103","author":"Nayak","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0200","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0145721707308407","article-title":"Medication taking and diabetes: A systematic review of the literature","volume":"33","author":"Odegard","year":"2007","journal-title":"The Diabetes Educator"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0175","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1463-1326.2011.01459.x","article-title":"Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: A 6-month 'proof-of-concept' study","volume":"13","author":"Owens","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0065","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0070","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0180","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0080","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc11-0632","article-title":"Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes","volume":"34","author":"Riddle","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0145","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0185","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jdiacomp.2013.04.008","article-title":"One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA target","volume":"27","author":"Rosenstock","year":"2013","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0010","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","volume":"28","author":"Ryden","year":"2007","journal-title":"European Heart Journal"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0075","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-8227(99)00061-3","article-title":"Postprandial plasma glucose: A good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels","volume":"46","author":"Soonthornpun","year":"1999","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0085","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9343(91)80085-Z","article-title":"Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group","volume":"90","author":"The Diabetes Control and Complications Trial Research Group","year":"1991","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0135","first-page":"28","article-title":"The impact of prandial glucose regulation in practice","volume":"15","author":"Verges","year":"2002","journal-title":"Diabetes, Nutrition & Metabolism"},{"key":"10.1016\/j.jdiacomp.2014.07.007_bb0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.regpep.2010.05.008","article-title":"Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"164","author":"Werner","year":"2010","journal-title":"Regulatory Peptides"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872714002074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872714002074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:07:48Z","timestamp":1761005268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872714002074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1056872714002074"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2014.07.007","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2014.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}